Due to the broad expression of PBK across multiple tumor types, specific inhibitors have been developed to target PBK, including HI-TOPK-03241, OTS514/OTS96442, and ADA-0743, and show high therapeutic potency in the preclinical study. Here, PBK is linked to neoplasm.